Co-authored by Patricia Granahan and Kenneth J. Dow
PROLOGUE: The world of pharmaceuticals and patent law can be exceedingly complex. Or, to twist Gertrude Stein's words, it is not correct that a drug is a drug is a drug. Nowhere is this more true than with "follow-on protein products," the term the U.S. Food and Drug Administration (FDA) adopted in 2004 for proteins intended as similar versions of already approved protein pharmaceutical products.
In a bit more detail (as explained by PrimeZone), follow-on protein products "are 'copies' of recombinant DNA-derived protein products made by companies other than the innovator [company] and using an abbreviated approval path. These products are generally more difficult to make than small-molecule generic drugs due to their greater complexity." Follow-on protein products are also sometimes referred to as generic biologics.
Click here to continue reading
Originally published by Health Affairs
The authors thank Audrey Phillips, Alan Bennett, Joanna Wu, and Greg Glover for their comments on this paper.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.